CLINICAL TRIAL: ADV HEAD & NECK CANCER AND OGF

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 晚期头颈部鳞状细胞癌（HNSCC）患者由于其肿瘤负荷和共病状况而难以治疗。在过去的30年里，这组不幸的患者的总体生存率没有显著提高。临床前研究表明，阿片样生长因子（OGF）及其受体，OGFr，形成一个紧张活性的生长抑制系统，靶向细胞复制在HNSCC。 在不可切除的胰腺癌患者中进行的I期研究在一定程度上是有效的。 OGF在人体中的安全性和最大耐受剂量已经确定，并已获得FDA批准。 本研究的目的是确定OGF-OGFr轴治疗50例晚期HNSCC患者的生存率和生活质量的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with advanced head and neck squamous cell cancer HNSCC) are difficult to treat due to their tumor burden and co-morbid conditions. Overall survival for this unfortunate group of patients has not improved, significantly, in the past 30 years. Preclinical studies have demonstrated that opiod growth factor (OGF) and its receptor, OGFr, form a tonically active growth inhibitory system that targets cell replication in HNSCC. Phase I studies in patients with unresectable pancreatic cancer has been somewhat efficacious. The safety and maximum tolerated dose of OGF, in humans, has been established and it has been approved by the FDA. The objective of this study is to determine the efficacy of the OGF-OGFr axis in the treatment of 50 patients with advanced HNSCC in terms of survival and quality of life.